TRMT44

Across TCGA pan-cancer cohorts, TRMT44 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of TRMT44’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TRMT44 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRMT44 is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

LIHC, COAD, and BRCA are the cancer types where TRMT44 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRMT44 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.701	<.001	8	view →
COAD	All	II,III,IV	+0.342	<.001	8	view →
BRCA	Female	II,III,IV	−0.289	<.001	6	view →
KICH	All	All	−0.547	<.001	4	view →
CHOL	Male	All	+1.210	<.001	3	view →
KIRP	Male	All	−0.417	.002	2	view →
READ	Female	All	+0.403	.014	2	view →
PAAD	Male	All	+0.294	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

TRMT44–LIHC

Open the LIHC breakdown →